Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)

NCT07129239 is registered in ClinicalTrials.gov with Clinique de Retine de l'est as lead sponsor.

NCT NCT07129239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07129239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
Lead sponsor
Clinique de Retine de l'est
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 20, 2025
Completion date
February 28, 2027
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration (wamd)